Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Study of AT-301 Nasal Spray in Healthy Adults
NCT04519788Phase 1Completed
- Sponsor
- Atossa Therapeutics
- Start
- Aug 2020
- Primary completion
- Dec 2020
- Modality
- Inhalation Devices, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing AT-301B with Placebo (2 arms). Primary endpoint: Cardiac, pulmonary and hemodynamic parameters using 12-lead ECG at 40 days. Started Aug 2020; status: completed.
02
Drugs
AT-301
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04519788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04519788.